Andrew Wei
0000-0002-7514-3298
Alfred Hospital
147 papers found
Refreshing results…
An international phase 3 randomized, placebo-controlled study of CC-486 (oral azacitidine) maintenance therapy in patients with acute myeloid leukemia (AML) in complete remission (CR): The Quazar AML maintenance trial.
Protocol of a multi-centre randomised controlled trial of a web-based information intervention with nurse-delivered telephone support for haematological cancer patients and their support persons
Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia
An Fc-modified antibody (CSL362) against CD123 augments the efficacy of chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice
Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation
Discovery and SAR of novel pyrazolo [1, 5-a] pyrimidines as inhibitors of CDK9
A randomised study on the safety of daily, intermittent, or weekly administration of 1, 3 or 10 mg kg (-1) of AmBisome as prophylaxis in acute leukaemics
Higher T Cell Numbers Is a Favourable Prognostic Factor in Acute Myeloid Leukaemia With Normal Cytogenetics
KB004, a Novel Non-Fucosylated Humaneered® Antibody, Targeting EphA3, Is Active and Well Tolerated in a Phase I/II Study of Advanced Hematologic Malignancies
T Cell Numbers Have Prognostic Value in Acute Myeloid Leukemia with Normal Cytogenetics
Maintenance Lenalidomide for Adults Aged 18-65 Years with AML in First Complete Remission after Intensive Chemotherapy: A Phase Ib Dose-Escalation Study of the Australasian Leukemia and Lymphoma Group (ALLG)
Eradication of Acute Myeloid Leukemia Is Enhanced By Combined Bcl-2 and Mcl-1 Targeting
ABT-199 partners with azacitidine to contest myeloid malignancies
Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia
Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care
Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients
Safe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myeloma
Optimal approach for high-risk acute promyelocytic leukemia
Author reply: To PMID 22757980.
S-15: Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia
Missing publications? Search for publications with a matching author name.